These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 13740326)

  • 1. Treatment of malignant disease with an alkylating agent: review of 100 patients treated with "Endoxan".
    REEVE TS
    Med J Aust; 1961 May; 48(1)():686-9. PubMed ID: 13740326
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide. A preliminary study of a new alkylating agent.
    FOYE LV; CHAPMAN CG; WILLETT FM; ADAMS WS
    Arch Intern Med; 1960 Sep; 106():365-7. PubMed ID: 13824275
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of a new alkylating agent: cytoxan (cyclophosphamide).
    COGGINS PR; RAVDIN RG; EISMAN SH
    Cancer; 1960; 13():1254-60. PubMed ID: 13694297
    [No Abstract]   [Full Text] [Related]  

  • 4. [1st clinical results of trials with cyclophosphamide (Endoxan) against malignant tumors].
    GARY-BOBO J; POURQUIER H; BELOTTE J
    Gaz Med Fr; 1962 Feb; 69():677-80. PubMed ID: 13897125
    [No Abstract]   [Full Text] [Related]  

  • 5. [The treatment of malignant hemoblastoses and neoplasms with Endoxan].
    KUEHBOECK J; REIMER EE; STOIBER T
    Arzneimittelforschung; 1961 Mar; 11():196-9. PubMed ID: 13754857
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative clinical evaluation of two alkylating agents: mannitol mustard and cyclophosphamide (cytoxan).
    PAPAC R; PETRAKIS NL; AMINI F; WOOD DA
    J Am Med Assoc; 1960 Mar; 172():1387-91. PubMed ID: 14430240
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparative study with three alkylating agents: mechlorethamine, cyclophosphamide, and uracil mustard.
    GOLD GL; SALVIN LG; SHNIDER BI
    Cancer Chemother Rep; 1962 Feb; 16():417-9. PubMed ID: 13899670
    [No Abstract]   [Full Text] [Related]  

  • 8. [Endoxan treatment of malignant tumors in otorhinolarygology].
    LOZERON H; LERUDULIER JL
    Praxis; 1961 Mar; 50():220-3. PubMed ID: 13763902
    [No Abstract]   [Full Text] [Related]  

  • 9. [Clinical experiences with the cyclic nitrogen mustard phosphamide ester, Endoxan in the treatment of malignant tumors].
    SCHARENBERG P; KAPISCHKE F
    Munch Med Wochenschr; 1962 Jan; 104():134-8. PubMed ID: 14498052
    [No Abstract]   [Full Text] [Related]  

  • 10. [Bilateral neoplasms of the orbit with lymphatic type elements treated with antimitotic agents (Endoxan)].
    BERTONCINI G; PARDUCCI F
    Ann Ottalmol Clin Ocul; 1961 Dec; 87():763-74. PubMed ID: 13868478
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experiences with endoxan in the treatment of maligant tumors].
    KIRSCHKE W
    Chirurg; 1961 Aug; 32():372-5. PubMed ID: 13756301
    [No Abstract]   [Full Text] [Related]  

  • 12. [Research with endoxan therapy of tumors in children].
    KOETTGEN U; WOLF M
    Med Klin; 1961 Jan; 56():15-8. PubMed ID: 15445395
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mitomen and endoxan: prophylactic and palliative treatment in connection with cancer surgery].
    SORENSEN B
    Ugeskr Laeger; 1959 Aug; 121():1241-6. PubMed ID: 13832874
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinical use of epoxypiperazine, a new alkylating agent, in the treatment of lymphomas and other neoplasms.
    MILLER DG; DIAMOND HD; CRAVER LF
    Cancer Res; 1959 Dec; 19():1204-9. PubMed ID: 14422486
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of metastases of carcinoma of the testis with endoxan].
    GALLE P
    Klin Med Osterr Z Wiss Prakt Med; 1961 Sep; 16():446-8. PubMed ID: 13896417
    [No Abstract]   [Full Text] [Related]  

  • 16. [Endoxan pretreatment in apparently inoperable ovarian carcinoma?].
    REICH E
    Geburtshilfe Frauenheilkd; 1962 Mar; 22():271-8. PubMed ID: 14491131
    [No Abstract]   [Full Text] [Related]  

  • 17. [Colposcopic, cytological and histological studies on the portio uteri under Endoxan treatment].
    KRAUSSOLD E; WENIG H
    Munch Med Wochenschr; 1960 Nov; 102():2410-1. PubMed ID: 13754119
    [No Abstract]   [Full Text] [Related]  

  • 18. [Ist clinical trials of a new nitrogen mustard, cyclophosphamide or Endoxan].
    LAMARQUE P; ROMIEU C; GARY-BOBO J; POURQUIER H; PUJOL H; BELOTTE J; DOSSA J; JAFFIOL C; LAMARQUE JL
    Sem Hop Ther Paris; 1961 Nov; 37():839-40. PubMed ID: 14461708
    [No Abstract]   [Full Text] [Related]  

  • 19. [The diphosphopyridine nucleotide blood level as a criterium for controlled dosage of cytostatics E 39 and endoxan in inoperable tumors].
    BOLT W; RITZL F; TOUSSAINT R; ZERLETT G
    Klin Wochenschr; 1960 Jan; 38():71-4. PubMed ID: 13802378
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of radioactive isotopes and alkylating agents in the treatment of malignant effusions.
    REEVE TS; MYHILL J
    Med J Aust; 1962 Aug; 49(2)():245-9. PubMed ID: 14491011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.